Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals - PubMed (original) (raw)
. 2014 Aug;100(2):657-66.
doi: 10.3945/ajcn.113.076349. Epub 2014 Jun 25.
Derrick Bennett 1, Sarah Parish 1, Sarah Lewington 1, Murray Skeaff 1, Simone J P M Eussen 1, Catharina Lewerin 1, David J Stott 1, Jane Armitage 1, Graeme J Hankey 1, Eva Lonn 1, J David Spence 1, Pilar Galan 1, Lisette C de Groot 1, Jim Halsey 1, Alan D Dangour 1, Rory Collins 1, Francine Grodstein 1; B-Vitamin Treatment Trialists’ Collaboration
Affiliations
- PMID: 24965307
- PMCID: PMC4095663
- DOI: 10.3945/ajcn.113.076349
Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals
Robert Clarke et al. Am J Clin Nutr. 2014 Aug.
Abstract
Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance of homocysteine lowering to slow the rate of cognitive aging is uncertain.
Objective: The aim was to assess the effects of treatment with B vitamins compared with placebo, when administered for several years, on composite domains of cognitive function, global cognitive function, and cognitive aging.
Design: A meta-analysis was conducted by using data combined from 11 large trials in 22,000 participants. Domain-based z scores (for memory, speed, and executive function and a domain-composite score for global cognitive function) were available before and after treatment (mean duration: 2.3 y) in the 4 cognitive-domain trials (1340 individuals); Mini-Mental State Examination (MMSE)-type tests were available at the end of treatment (mean duration: 5 y) in the 7 global cognition trials (20,431 individuals).
Results: The domain-composite and MMSE-type global cognitive function z scores both decreased with age (mean ± SE: -0.054 ± 0.004 and -0.036 ± 0.001/y, respectively). Allocation to B vitamins lowered homocysteine concentrations by 28% in the cognitive-domain trials but had no significant effects on the z score differences from baseline for individual domains or for global cognitive function (z score difference: 0.00; 95% CI: -0.05, 0.06). Likewise, allocation to B vitamins lowered homocysteine by 26% in the global cognition trials but also had no significant effect on end-treatment MMSE-type global cognitive function (z score difference: -0.01; 95% CI: -0.03, 0.02). Overall, the effect of a 25% reduction in homocysteine equated to 0.02 y (95% CI: -0.10, 0.13 y) of cognitive aging per year and excluded reductions of >1 mo per year of treatment.
Conclusion: Homocysteine lowering by using B vitamins had no significant effect on individual cognitive domains or global cognitive function or on cognitive aging.
Figures
FIGURE 1.
Effects of B vitamins on specific domains of cognitive function and on a domain-composite score by using change from baseline in the cognitive-domain trials. The z scores for individual trials and the total for the cognitive-domain trials are shown separately for memory, speed, and executive function and for a domain-composite global cognitive function score. Black squares represent z score differences for the individual trials and the horizontal lines represent 95% CIs. The size of the squares is inversely proportional to the variance. Diamonds represent the z scores and 95% CIs for all trials.
FIGURE 2.
Effects of B vitamins on MMSE-type global cognitive function score at the end of the treatment period in the global cognition trials. The z score for differences and their 95% CIs for MMSE-type global cognitive function scores are shown for individual trials and as the total for all trials. The z score differences are for B-vitamins compared with placebo. * refers to B-vitamin based treatment vs placebo. HOPE-2, Heart Outcomes Prevention Evaluation-2; MMSE, Mini-Mental State Examination; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SU.FOL.OM3, Supplementation with Folate, vitamin B6 and B12 and/or Omega-3 fatty acids; VISP, Vitamin Intervention for Stroke Prevention; VITATOPS, Vitamins to Prevent Stroke; WAFACS, Women's Antioxidant and Folic Acid Cardiovascular Study.
FIGURE 3.
Effects of B vitamins on cognitive aging in all available trials per year at a 25% reduction in homocysteine. The z score differences and their 95% CIs are provided for the domain-composite global cognitive function score in each cognitive-domain trial and for the MMSE-type global cognitive function score in the other trials. The years of cognitive aging equivalent and their 95% CIs are also provided for individual trials and their totals. The years of cognitive aging equivalent were determined on the basis of a 0.054/y reduction in the cognitive domain trial score and a 0.036/y reduction in the global cognition trial score. * indicates that the age association was based on 0.054 per year reduction in domain-composite z score for cognitive-domain trials and on 0.036 per year reduction in MMSE-type cognitive z score. FACIT, Folic Acid and Carotid Intima-Media Thickness; HOPE-2, Heart Outcomes Prevention Evaluation-2; MMSE, Mini-Mental State Examination; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SU.FOL.OM3, Supplementation with Folate, vitamin B6 and B12 and/or Omega-3 fatty acids; tHcy, total homocysteine; VISP, Vitamin Intervention for Stroke Prevention; VITATOPS, Vitamins to Prevent Stroke; WAFACS, Women's Antioxidant and Folic Acid Cardiovascular Study.
Comment in
- B-vitamin trials meta-analysis: less than meets the eye.
Garrard P, Jacoby R. Garrard P, et al. Am J Clin Nutr. 2015 Feb;101(2):414-5. doi: 10.3945/ajcn.114.097808. Am J Clin Nutr. 2015. PMID: 25646342 No abstract available. - Homocysteine lowering, B vitamins, and cognitive aging.
Smith AD, de Jager CA, Refsum H, Rosenberg IH. Smith AD, et al. Am J Clin Nutr. 2015 Feb;101(2):415-6. doi: 10.3945/ajcn.114.098467. Am J Clin Nutr. 2015. PMID: 25646343 No abstract available. - Reply to Garrard and Jacoby and Smith et al.
Clarke R, Bennett D, Parish S; B-Vitamin Treatment Trialists’ Collaboration. Clarke R, et al. Am J Clin Nutr. 2015 Feb;101(2):416-7. doi: 10.3945/ajcn.114.100941. Am J Clin Nutr. 2015. PMID: 25646344 No abstract available.
Similar articles
- Homocysteine lowering, B vitamins, and cognitive aging.
Smith AD, de Jager CA, Refsum H, Rosenberg IH. Smith AD, et al. Am J Clin Nutr. 2015 Feb;101(2):415-6. doi: 10.3945/ajcn.114.098467. Am J Clin Nutr. 2015. PMID: 25646343 No abstract available. - B-vitamin trials meta-analysis: less than meets the eye.
Garrard P, Jacoby R. Garrard P, et al. Am J Clin Nutr. 2015 Feb;101(2):414-5. doi: 10.3945/ajcn.114.097808. Am J Clin Nutr. 2015. PMID: 25646342 No abstract available. - A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients.
Kwok T, Wu Y, Lee J, Lee R, Yung CY, Choi G, Lee V, Harrison J, Lam L, Mok V. Kwok T, et al. Clin Nutr. 2020 Aug;39(8):2399-2405. doi: 10.1016/j.clnu.2019.11.005. Epub 2019 Nov 20. Clin Nutr. 2020. PMID: 31787369 Clinical Trial. - Homocysteine, B Vitamins, and Cognitive Impairment.
Smith AD, Refsum H. Smith AD, et al. Annu Rev Nutr. 2016 Jul 17;36:211-39. doi: 10.1146/annurev-nutr-071715-050947. Annu Rev Nutr. 2016. PMID: 27431367 Review. - Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases.
Zhang DM, Ye JX, Mu JS, Cui XP. Zhang DM, et al. J Geriatr Psychiatry Neurol. 2017 Jan;30(1):50-59. doi: 10.1177/0891988716673466. Epub 2016 Oct 17. J Geriatr Psychiatry Neurol. 2017. PMID: 28248558 Review.
Cited by
- Diet Pattern Analysis in Alzheimer's Disease Implicates Gender Differences in Folate-B12-Homocysteine Axis on Cognitive Outcomes.
Ting CP, Ma MC, Chang HI, Huang CW, Chou MC, Chang CC. Ting CP, et al. Nutrients. 2024 Mar 4;16(5):733. doi: 10.3390/nu16050733. Nutrients. 2024. PMID: 38474861 Free PMC article. - Global heterogeneity in folic acid fortification policies and implications for prevention of neural tube defects and stroke: a systematic review.
Quinn M, Halsey J, Sherliker P, Pan H, Chen Z, Bennett DA, Clarke R. Quinn M, et al. EClinicalMedicine. 2023 Dec 12;67:102366. doi: 10.1016/j.eclinm.2023.102366. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38169713 Free PMC article. - Computationally Modelling Cholesterol Metabolism and Atherosclerosis.
Davies C, Morgan AE, Mc Auley MT. Davies C, et al. Biology (Basel). 2023 Aug 14;12(8):1133. doi: 10.3390/biology12081133. Biology (Basel). 2023. PMID: 37627017 Free PMC article. - Effect of a 1-Year Nutritional Blend Supplementation on Plasma p-tau181 and GFAP Levels among Community-Dwelling Older Adults: A Secondary Analysis of the Nolan Trial.
Giudici KV, de Souto Barreto P, Guyonnet S, Cantet C, Zetterberg H, Boschat C, Hudry J, Andrieu S, Schmitt JAJ, Vellas B, Blennow K; NOLAN/DSA group. Giudici KV, et al. JAR Life. 2023 Jun 12;12:25-34. doi: 10.14283/jarlife.2023.7. eCollection 2023. JAR Life. 2023. PMID: 37351539 Free PMC article. - Neurological Implications of Vitamin B12 Deficiency in Diet: A Systematic Review and Meta-Analysis.
Alruwaili M, Basri R, AlRuwaili R, Albarrak AM, Ali NH. Alruwaili M, et al. Healthcare (Basel). 2023 Mar 27;11(7):958. doi: 10.3390/healthcare11070958. Healthcare (Basel). 2023. PMID: 37046885 Free PMC article. Review.
References
- Mayeux R. Early Alzehimer's disease. N Engl J Med 2010;362:2194–201. - PubMed
- Clarke R, Smith AD, Jobst K, Sutton L, Refsum H, Ueland PM. Plasma homocysteine, folate and vitamin B-12 as risk factors for confirmed Alzheimer's disease. Arch Neurol 1998;55:1449–55. - PubMed
- Clarke R. B-vitamins and prevention of dementia. Proc Nutr Soc 2008;67:75–81. - PubMed
- Clarke R, Birks J, Nexo E, Ueland PM, Schneede PM, Scott J, Molloy A, Frost C, Evans JM. Low vitamin B12 status and risk of cognitive decline in older people. Am J Clin Nutr 2007;86:1384–91. - PubMed
- Seshadri S, Beiser A, Selhub J, Jacques P, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476–83. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MC_U137686857/MRC_/Medical Research Council/United Kingdom
- BHF_/British Heart Foundation/United Kingdom
- CRUK_/Cancer Research UK/United Kingdom
- DH_/Department of Health/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical